[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100601950":3},{"organization":4,"outcomesModule":7,"designInfo":23,"detailedDescription":22,"studyPopulation":22,"armGroups":29,"interventions":40,"overallOfficials":22,"centralContacts":45,"locations":54,"responsibleParty":74,"collaborators":22,"id":76,"slug":22,"hasResults":77,"nctId":78,"briefTitle":79,"officialTitle":80,"acronym":22,"eligibilityCriteria":81,"healthyVolunteers":77,"sex":82,"minAge":83,"maxAge":22,"enrollmentInfo":84,"targetDuration":22,"studyType":87,"phases":88,"briefSummary":90,"conditions":91,"keywords":22,"overallStatus":56,"whyStopped":22,"lastUpdateSubmitDate":93,"lastUpdatePostDateStruct":94,"startDateStruct":97,"completionDateStruct":99,"leadSponsor":101,"locationsCount":102},{"fullName":5,"class":6},"VA Pittsburgh Healthcare System","FED",{"primaryOutcomes":8,"secondaryOutcomes":17,"otherOutcomes":22},[9,13],{"measure":10,"description":11,"timeFrame":12},"Time to Eligibility Determination","Compare the number of days from randomization to the determination of eligibility for monoclonal antibody therapy for both the intervention and usual care groups, assessed up to 12 months.","From date of randomization until the date of determination of eligibility for monoclonal antibody therapy, assessed up to 12 months.",{"measure":14,"description":15,"timeFrame":16},"Time to Initial Infusion","Compare the number of days from the date of randomization to the initial infusion of monoclonal antibody therapy for both the intervention and usual care groups, assessed up to 12 months.","From date of randomization until the date of first infusion, assessed up to 12 months.",[18],{"measure":19,"description":20,"timeFrame":21},"Number of Participants and Instances of Additional testing","Chart review will be used to determine the number of participants who underwent additional testing and the total number of additional tests performed. This includes counting instances of APOE genetic testing, MRI brain imaging, and amyloid PET imaging as ordered at the discretion of the specialist.","1 year",null,{"allocation":24,"interventionModel":25,"interventionModelDescription":22,"primaryPurpose":26,"observationalModel":22,"timePerspective":22,"maskingInfo":27},"RANDOMIZED","SINGLE_GROUP","HEALTH_SERVICES_RESEARCH",{"masking":28,"maskingDescription":22,"whoMasked":22},"NONE",[30,36],{"label":31,"type":32,"description":33,"interventionNames":34},"ADRD Care Delivery Protocol","EXPERIMENTAL","Patients will undergo telehealth preparedness assessment, cognitive screening, and blood biomarker testing prior to the initial consultation with the specialist.",[35],"Other: ADRD Care Delivery Protocol",{"label":37,"type":38,"description":39,"interventionNames":22},"Usual Care","NO_INTERVENTION","Patients will undergo usual care with all evaluation and testing at the discretion of the specialist.",[41],{"type":42,"name":31,"description":43,"armGroupLabels":44,"otherNames":22},"OTHER","1\\. Included in arm\u002Fgroup descriptions",[31],[46,51],{"name":47,"role":48,"phone":49,"phoneExt":22,"email":50},"Alison O'Donnell, DO, MPH","CONTACT","412-522-3123","alison.odonnell2@va.gov",{"name":52,"role":48,"phone":22,"phoneExt":22,"email":53},"Julie Faieta, PhD","juf52@pitt.edu",[55],{"facility":5,"status":56,"city":57,"state":58,"zip":59,"country":60,"countryCode":61,"cosmosGeoPoint":62,"geoPoint":67,"contacts":68},"RECRUITING","Pittsburgh","Pennsylvania","15240","United States","US",{"type":63,"coordinates":64},"Point",[65,66],-79.99589,40.44062,{"lat":66,"lon":65},[69,70,71,73],{"name":47,"role":48,"phone":49,"phoneExt":22,"email":50},{"name":52,"role":48,"phone":22,"phoneExt":22,"email":53},{"name":47,"role":72,"phone":22,"phoneExt":22,"email":22},"PRINCIPAL_INVESTIGATOR",{"name":52,"role":72,"phone":22,"phoneExt":22,"email":22},{"type":75,"investigatorFullName":22,"investigatorTitle":22,"investigatorAffiliation":22,"oldNameTitle":22,"oldOrganization":22},"SPONSOR","100601950",false,"NCT07117162","Improving Access to Care for Veterans With Memory Loss","Increasing Access to Care: An Advanced Virtual Care Delivery Protocol to Deliver Diagnostic and Therapeutic Services to Underserved Veterans With ADRD","Inclusion Criteria:\n\n* Diagnosis of mild cognitive impairment or mild dementia due to suspected or confirmed AD with a 5 minute telephone MoCA score \\>7\n* Meets VA MUE inclusion\u002Fexclusion criteria for mAb therapy for AD\n* Enrolled in VA care\n* Lives in a home setting (i.e., not in an institutional setting such as a nursing home, Community Living Center, or hospital)\n* Has a working telephone\n* 18 years and older\n* Able to communicate in English\n* Willing to give informed consent.\n\nExclusion Criteria:\n\n* None","ALL","18 Years",{"count":85,"type":86},30,"ESTIMATED","INTERVENTIONAL",[89],"NA","This study evaluates a care delivery protocol to improve access to care for Veterans with Alzheimer's Disease and Related Disorders (ADRD). A randomized controlled trial will enroll Veterans with mild cognitive impairment or early dementia at VA Pittsburgh. The ADRD care delivery protocol integrates telehealth, advanced diagnostics, and streamlined workflows to expedite screening for eligibility for amyloid targeting therapies.",[92],"Alzheimer Disease","2025-10-30",{"date":95,"type":96},"2025-11-03","ACTUAL",{"date":98,"type":96},"2025-10-29",{"date":100,"type":86},"2027-06",{"name":5,"class":6},1]